Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Assets: 2023-2025

Historic Assets for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $459.8 million.

  • Monte Rosa Therapeutics' Assets rose 45.94% to $459.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $459.8 million, marking a year-over-year increase of 45.94%. This contributed to the annual value of $438.7 million for FY2024, which is 44.44% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Assets stood at $459.8 million for Q3 2025, which was up 27.88% from $359.6 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Assets ranged from a high of $459.8 million in Q3 2025 and a low of $252.1 million during Q3 2023.
  • Moreover, its 3-year median value for Assets was $315.1 million (2024), whereas its average is $338.3 million.
  • In the last 5 years, Monte Rosa Therapeutics' Assets fell by 13.68% in 2024 and then surged by 47.41% in 2025.
  • Monte Rosa Therapeutics' Assets (Quarterly) stood at $303.8 million in 2023, then spiked by 44.44% to $438.7 million in 2024, then spiked by 45.94% to $459.8 million in 2025.
  • Its Assets stands at $459.8 million for Q3 2025, versus $359.6 million for Q2 2025 and $393.2 million for Q1 2025.